Literature DB >> 11397878

Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors.

M Korbonits1, I Bujalska, M Shimojo, J Nobes, S Jordan, A B Grossman, P M Stewart.   

Abstract

One of the defining biochemical features of Cushing's disease is a relative insensitivity to glucocorticoid (GC) feedback, but an analysis of the GC receptor has failed to detect any major abnormalities. However, two isoenzymes of 11 beta-hydroxysteroid dehydrogenase (11 beta HSD), either by converting cortisone (E) to cortisol (F) (type 1) or conversely by converting F to E (type 2), play an important prereceptor role in regulating corticosteroid hormone action at several sites. 11 beta HSD1 and -2 expression within the anterior pituitary gland itself may modulate GC feedback at an autocrine level, and we have speculated that this may be deranged in Cushing's disease. Detection of 11 beta HSD type 1 and 2 immunoreactive protein was performed using fluorescence immunohistochemistry. Double immunofluorescent studies were undertaken on normal pituitary to define the cellular localization of 11 beta HSD isoenzymes using antisera against GH, ACTH, LH, FSH, PRL, and S100, a nonhormonal marker of folliculo-stellate cells. In normal pituitary, positive staining for 11 beta HSD1-immunoreactive protein was observed in GH- and PRL-secreting cells and in folliculo-stellate cells; gonadotrophs, thyrotrophs, and ACTH-positive cells were negative. 11 beta HSD2 immunoreactivity was absent in all cell types. RT-PCR detected 11 beta HSD1 messenger ribonucleic acid (mRNA) expression in the normal pituitary; 11 beta HSD2 mRNA expression was also seen in most normal tissue. By contrast, in ACTH-secreting adenomas 11 beta HSD2 immunostaining was strongly positive in every case of corticotroph adenoma. 11 beta HSD1 immunoreactivity was also observed occasionally, but to a much lesser extent. In other pituitary tumors, both functional and nonfunctional, 11 beta HSD expression was variable in terms of isoenzyme mRNA and intensity of protein staining. The expression of 11 beta HSD1 (which generates F from E) in somatotrophs and lactotrophs suggests an autocrine role for this isoenzyme in the glucocorticoid regulation of pituitary GH and PRL secretion. 11 beta HSD2 expression is markedly induced in ACTH-secreting pituitary tumors and, by converting F to E, may explain the resetting of glucocorticoid feedback control in Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397878     DOI: 10.1210/jcem.86.6.7563

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma.

Authors:  Takanori Ebisawa; Katsuyoshi Tojo; Naoko Tajima; Masami Kamio; Yutaka Oki; Katsuhiko Ono; Hironobu Sasano
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Can licorice lick colon cancer?

Authors:  Paul M Stewart; Stephen M Prescott
Journal:  J Clin Invest       Date:  2009-04       Impact factor: 14.808

Review 3.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

4.  Overnight ACTH-cortisol dose responsiveness: comparison with 24-h data, metyrapone administration and insulin-tolerance test in healthy adults.

Authors:  Ali Iranmanesh; Daniel M Keenan; Paul Aoun; Johannes D Veldhuis
Journal:  Clin Endocrinol (Oxf)       Date:  2011-11       Impact factor: 3.478

Review 5.  The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

Authors:  George Briassoulis; Svetozar Damjanovic; Paraskevi Xekouki; Hervé Lefebvre; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

Review 6.  The molecular biology of pituitary tumors: a personal perspective.

Authors:  Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

7.  Different levels of various glucocorticoid-regulated genes in corticotroph adenomas.

Authors:  Johan Arild Evang; Jens Bollerslev; Olivera Casar-Borota; Tove Lekva; Jon Ramm-Pettersen; Jens Petter Berg
Journal:  Endocrine       Date:  2013-01-13       Impact factor: 3.633

8.  FGFR4 polymorphic variants modulate phenotypic features of Cushing disease.

Authors:  Tae Nakano-Tateno; Toru Tateno; Maw Maw Hlaing; Lei Zheng; Katsuhiko Yoshimoto; Shozo Yamada; Sylvia L Asa; Shereen Ezzat
Journal:  Mol Endocrinol       Date:  2014-03-13

Review 9.  11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action.

Authors:  Karen Chapman; Megan Holmes; Jonathan Seckl
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

10.  Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback.

Authors:  Yasutaka Tsujimoto; Hiroki Shichi; Hidenori Fukuoka; Masaaki Yamamoto; Itsuko Sato; Takamitsu Imanishi; Tomoaki Nakamura; Naoko Inoshita; Atsushi Ishida; Shozo Yamada; Yutaka Takahashi; Kazuo Chihara
Journal:  J Endocr Soc       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.